Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by skier59on Aug 02, 2022 9:38pm
259 Views
Post# 34867152

RE:RE:Theralase Safety During Market Erosion

RE:RE:Theralase Safety During Market Erosion Yup, this is it. The final countdown. What we LONGS have been here for sooooo many years. Bought too early, maybe, but believed in the dream, and the long term Goal. These next 1-4 months should tell us the optimised story, and some durability data, which then should hopefully start to drive some serious SP appreciation. 



ScienceFirst wrote: Data on 11 patients that had received their 2nd dose but for which we had not received yet a status should be THE focus to watch on whether they turned CR @270 days on how many of them (%) reached this CR. The % would help assess what we could expect from optimized patients group.   That could be very telling.


<< Previous
Bullboard Posts
Next >>